Impact of short term use of interdialytic 60% ethanol lock solution on tunneled silicone catheter dysfunction

Clinical Nephrology

Volumn 75, Issue 6, 2011, Pages 534-541

  Heng, A E ^a   Abdelkader, M H ^a   Diaconita, M ^b   Nony, A ^c   Guerraoui, A ^d   Caillot, N ^e   Rince, M ^b   Deteix, P ^a,f   Souweine, B ^a,f  

^a SERVICE DE RHUMATOLOGIE   (France)

^b DUPUYTREN UNIVERSITY HOSPITAL   (France)

^c Centre Hospitalier Jacques Coeur   (France)

^d Centre Hospitalier de Vichy   (France)

^e UFR Médecine ^*  (France)

^f UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

Catheter patency; Ethanol lock; Huemodialysis; Silicone catheter dysfunction

Indexed keywords

ALCOHOL; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CITRIC ACID; FIBRINOLYTIC AGENT; HEPARIN; INTERDIALYTIC ETHANOL LOCK SOLUTION; INTERDIALYTIC STANDARD LOCK SOLUTION; UNCLASSIFIED DRUG; UROKINASE; SILICONE DERIVATIVE; TOPICAL ANTIINFECTIVE AGENT;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CATHETER DYSFUNCTION; CATHETER INFECTION; CATHETER REMOVAL; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSIS CATHETER; FEMALE; FIBRINOLYSIS; HEMODIALYSIS; HUMAN; MALE; PARAMETER; PROSPECTIVE STUDY; SILASTIC TUBE; UREA BLOOD LEVEL; CENTRAL VENOUS CATHETERIZATION; CHEMISTRY; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; EQUIPMENT; INDWELLING CATHETER; INFECTION; INSTRUMENTATION; MATERIALS TESTING; PROSTHESIS FAILURE; RENAL REPLACEMENT THERAPY;

AGED; ANTI-INFECTIVE AGENTS, LOCAL; CATHETERIZATION, CENTRAL VENOUS; CATHETERS, INDWELLING; CHI-SQUARE DISTRIBUTION; EQUIPMENT CONTAMINATION; ETHANOL; FEMALE; HUMANS; MALE; MATERIALS TESTING; PROSPECTIVE STUDIES; PROSTHESIS FAILURE; PROSTHESIS-RELATED INFECTIONS; RENAL DIALYSIS; SILICONES;

EID: 79960940148     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN106559     Document Type: Article

References (35)

1. National Kidney Foundation. K/DOQI clinical practice guidelines for vascular access, 2006.AmJ Kidney Dis. 2006; 48: 248-257.
2. Astor BC, Eustace JA, Powe NR, Klag MJ, Fink NE, Coresh J. CHOICE Study. Type o fvascular access and survival among incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study. J Am Soc Nephrol. 2005; 16: 1449-1455.
3. Lafrance JP, Rahme E, Lelorier J, Iqbal S. Vascular access-related infections: definitions, incidence rates, and risk factors. Am J Kidney Dis. 2008; 52: 982-993.
4. Allon M. Dialysis catheter-related bacteremia: treatment and prophylaxis. Am J Kidney Dis. 2004; 44: 779-791.
5. Weijmer MC, van den Dorpel MA, Van de Ven PJ, ter Wee PM, van Geelen JA, Groeneveld JO, van Jaarsveld BC, Koopmans MG, le Poole CY, Schrander-Van der Meer AM, Siegert CE, Stas KJ. CITRATE Study Group Randomized, clinical trial comparison of trisodium citrate 30% and heparin as catheter-locking solution in hemodialysis patients. J Am Soc Nephrol. 2005; 16: 2769-2777.
6. Yahav D, Rozen-Zvi B, Gafter-Gvili A, Leibovici L, Gafter U, Paul M. Antimicrobial lock solutions for the prevention of infections associated with intravascular catheters in patients undergoing hemodialysis: systematic review and meta-analysis of randomized, controlled trials. Clin Infect Dis. 2008; 47: 83-93.
7. Jaffer Y, Selby NM, Taal MW, Fluck RJ, McIntyre CW. A meta-analysis of hemodialysis catheter locking solutions in the prevention of catheter-related infection. Am J Kidney Dis. 2008; 51: 233-241.
8. Labriola L, Crott R, Jadoul M. Preventing haemodialysis catheter-related bacteraemia with an antimicrobial lock solution: a meta-analysis ofprospective randomized trials. Nephrol Dial Transplant. 2008; 23: 1666-1672.
9. Katneni R, Hedayati. Central venous catheter-related bacteremia in chronic haemodialysis patients: epidemiology and evidence-based management. Nat Clin Pract Nephrol. 2007; 3: 256-266.
10. Balestrino D, Souweine B, Charbonnel N, Lautrette A, Aumeran C, Traore O, Forestier C. Eradication of microorganisms embedded in biofilm by an ethanol-based catheter lock solution. Nephrol Dial Transplant. 2009; 1-5: doi: 10.1093/ndt/gfp187.
11. FDA issues warning on triCitrasol® dialysis catheter anticoagulant. FDA Talk Paper T00-16, 14 April 2000.
12. Power A, Duncan N, Singh SK, BrownW, Dalby E, Edwards C, Lynch K, Prout V, Cairns T, Griffith M, McLean A, Palmer A, Taube D. Sodium citrate versus heparin catheter locks for cuffed central venous catheters: a single-center randomized controlled trial. Am J Kidney Dis. 2009; 53: 1034-1041.
13. Steczko J, Ash SR, Nivens DE, Brewer L, Winger RK. Microbial inactivation properties of a new antimicrobial/antithrombotic catheter lock solution (citrate/methylene blue/parabens). Nephrol Dial Transplant. 2009; 24: 1937-1945.
14. Pittet D, Allegranzi B, Sax H, Dharan S, Pessoa-Silva CL, Donaldson L, Boyce JM; WHO Global Patient Safety Challenge, World Alliance for Patient Safety. Evidence-based model for hand transmission during patient care and the role of improved practices. Lancet Infect Dis. 2006; 6: 641-652.
15. Pennington CR, Pithie AD. Ethanol lock in the management of catheter occlusion. J Parenter Enteral Nutr. 1987; 11: 507-508.
16. Ball PA, Brokenshire E, Parry B et al. Ethanol locking as a possible treatment for microbial contamination of long-term central venous catheters. Nutrition. 2003; 19: 570.
17. Metcalf SCL, Chambers ST, Pithie AD. Use of ethanol locks to prevent recurrent central line sepsis. J Infect. 2004; 49: 20-22.
18. Ackoundou-N'Guessan C, Heng AE, Guenu S, Charbonne F, Traore O, Deteix P, Souweine B. Ethanol lock solution as an adjunct treatment for preventing recurrent catheter-related sepsis - first case report in dialysis setting. Nephrol Dial Transplant. 2006; 21: 3339-3340.
19. Opilla MT, Kirby DF, Edmond MB. Use of ethanol lock therapy to reduce the incidence of catheter-related bloodstream infections in home parenteral nutrition patients. JPEN J Parenter Enteral Nutr. 2007; 31: 302-305.
20. Broom J, Woods M, Allworth A, McCarthy J, Faoagali J, Macdonald S, Pithie A. Ethanol lock therapy to treat tunneled central venous catheter-associated blood stream infections: results from a prospective trial. Scand J Infect Dis. 2008; 40: 399-406.
21. Sanders J, Pithie A, Ganly P, Surgenor L, Wilson R, Merriman E, Loudon G, Judkins R, Chambers S. A prospective double-blind randomized trial comparing intraluminal ethanol with heparinized saline for the prevention of catheter-associated bloodstream infection in immunosuppressed haematology patients. J Antimicrob Chemother. 2008; 62: 809-815.
22. Dannenberg C, Bierbach U, Rothe A, Beer J, Korholz D. Ethanol-lock technique in the treatment of bloodstream infections in pediatric oncology patients with broviac catheter. J Pediatr Hematol Oncol. 2003; 5: 616-621.
23. Onland W, Shin CE, Fustar S, Rushing T, Wong WY. Ethanol-lock technique for persistent bacteremia of long-term intravascular devices in pediatric patients. Arch Pediatr Adolesc Med. 2006; 160: 1049-1053.
24. Mouw E, Chessman K, Lesher A, Tagge E. Use of an ethanol lock to prevent catheter-related infections in children with short bowel syndrome. J Pediatr Surg. 2008; 43: 1025-1029.
25. Crnich CJ, Halfmann JA, Crone WC, Maki DG. The effects of prolonged ethanol exposure on the mechanical properties of polyurethane and silicone catheters used for intravascular access. Infect Control Hosp Epidemiol. 2005; 26: 708-714.
26. Guenu S, Heng AE, Charbonné F, Galmier MJ, Charlès F, Deteix P, Souweine B, Lartigue C. Mass spectrometry and scanning electron microscopy study of silicone tunneled dialysis catheter integrity after an exposure of 15 days to 60% ethanol solution. Rapid Commun Mass Spectrom. 2007; 21: 229-236.
27. Sopwith W, Hart T, Garner P. Preventing infection from reusable medical equipment: a systematic review. BMC Infect Dis. 2002; 2: 1-10.
28. Sissons CH, Wong L, Cutress TW. Inhibition by ethanol of the growth of biofilm and dispersed microcosm dental plaques. Arch Oral Biol. 1996; 41: 27-34.
29. Chambers ST, Pithie A, Gallagher K, Liu T, Charles CJ, Seaward L. Treatment of Staphylococcus epidermidis central vascular catheter infection with 70% ethanol locks: efficacy in a sheep model. J Antimicrob Chemother. 2007; 59: 779-782.
30. Takla TA, Zelenitsky SA, Vercaigne LM. Effectiveness of a30% ethanol/4% trisodium citrate locking solution in preventing biofilm formation by organisms causing haemodialysis catheter-related infections. J Antimicrob Chemother. 2008; 62: 1024-1026.
31. Raad I, Hanna H, Dvorak T, Chaiban G, Hachem R. Optimal antimicrobial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percent ethanol, rapidly eradicates organisms embedded in biofilm. Antimicrob Agents Chemother. 2007; 51: 78-83.
32. Polaschegg HD. Catheter locking-solution spillage: theory and experimental verification. Blood Purif. 2008; 26: 255-260.
33. Chan MR. Hemodialysis central venous catheter dysfunction. Semin Dial. 2008; 21: 516-521.
34. Power A, Duncan N, Singh SK, BrownW, Dalby E, Edwards C, Lynch K, Prout V, Cairns T, Griffith M, McLean A, Palmer A, Taube D. Sodium citrate versus heparin catheter locks for cuffed central venous catheters: a single center randomized contolled trial. Am J Kidney Dis. 2009; 53: 1034-1041.
35. Depner TA. Catheter performance. Semin Dial. 2001; 1: 425-431.